CVS Health (CVS) PT Trimmed to $110 at Credit Suisse
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Credit Suisse analyst Robert Willoughby trimmed his price target on CVS Health (NYSE: CVS) to $110.00 (from $115.00) but maintained an Outperform rating after news the US Department of Defense military health program, announced that as of December 1, CVS will no longer be a part of its pharmacy network, replaced by competitor Walgreens.
Willoughby commented, "CVS was on the winning side of a 2011 dispute between Express Scripts and Walgreens that saw Walgreens removed from TRICARE's pharmacy network. The news is consistent with recent efforts by Walgreens to align itself more with payors to gain more pharmacy market share, curbing CVS's opportunity."
The firm is lowering 2017 EPS estimate to $6.55 (from $6.60) on a weaker revenue outlook.
Shares of CVS Health closed at $88.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Workday (WDAY) to $71 Following 3Q
- Jefferies Raises Price Target on Zumiez, Inc. (ZUMZ) to $23 Following 3Q
- Jefferies Raises Price Target on Ulta Salon (ULTA) to $270; Reiterates Hold
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesCredit Suisse, Robert Willoughby
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!